Journal Article

Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study

Gunnar Klein, Christoph Lissel, Anne-Catherine Fuchs, Ajmal Gardiwal, Hanno Oswald, Marcos deSousa, A. Maximilian Pichlmaier, Ralf Lichtinghagen, Heinz Geerlings, Peter Lippolt, Michael Niehaus, Helmut Drexler and Thomas Korte

in EP Europace

Published on behalf of European Heart Rhythm Association of the European Society of Cardiology (ESC)

Volume 8, issue 8, pages 618-624
Published in print August 2006 | ISSN: 1099-5129
Published online August 2006 | e-ISSN: 1532-2092 | DOI: http://dx.doi.org/10.1093/europace/eul082
Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study

Show Summary Details

Preview

Aims Identification of risk factors for ventricular tachycardia/ventricular fibrillation (VT/VF) occurrence in patients with implantable cardioverter-defibrillators (ICD) is reasonable, because ICD patients with multiple risk factors might benefit from more aggressive anti-arrhythmic therapy for the prevention of arrhythmic events. Furthermore, in the era of prophylactic ICD therapy and limited healthcare resources, additional markers are needed for improved patient selection.

Methods and results Thus, in Prospective Analysis of Risk Factor for Appropriate ICD Therapy (PROFIT), we prospectively analyzed the role of ejection fraction (EF), N-terminal probrain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) class, atrial fibrillation, and QRS-duration as independent predictors for VT/VF occurrence in 250 ICD patients. Kaplan–Meier analysis showed that EF<40% (log-rank P=0.001), NT-proBNP levels higher than median (≥405 ng/L; log-rank P=0.04), QRS-duration ≥150 ms (log-rank P=0.016), permanent atrial fibrillation (log-rank P=0.008), and higher NYHA class (log-rank P=0.029) were associated with VT/VF occurrence. By multivariate Cox regression analysis EF, QRS-duration and atrial fibrillation remained significantly associated with appropriate VT/VF therapy, whereas there was no relationship among NT-proBNP, NYHA class, and VT/VF occurrence. Stratifying patients according to the number of their independent risk factors (EF<40%, AF, QRS-width≥150 ms) showed that patients with greater than or equal to two risk factors had a 100% 2-year risk of VT/VF occurrence, whereas patients with no or one risk factor had a 19.3 and 25% 2-year risk, respectively.

Conclusions EF<40%, permanent atrial fibrillation, and QRS≥150 ms are independent predictors for VT/VF occurrence in predominantly secondary prophylactic ICD patients. Combining all independent predictors, we developed a risk score for VT/VF occurrence identifying a subgroup of patients with two or more risk factors who had a 100% 2-year risk. Future studies will reveal if this risk score helps to identify ICD patients suitable for empirical anti-arrhythmic therapy and to improve patient selection for prophylactic ICD therapy.

Keywords: Implantable cardioverter-defibrillator; Risk factors for VT/VF occurrence; Ventricular tachyarrhythmias

Journal Article.  3479 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.